L A B D O C

Independent Verification

TEST REPORT

CERTIFICATE OF ANALYSIS

REPORT ID	SAMPLE RECEIVED	DATE TESTED
LD-ZACL	16 OCTOBER 2026	20 OCTOBER 2026

01 / SAMPLE DETAILS

BPC-157 + TB-500

Lyophilized Powder (Vial)

Client	
Company	**Peak Peptides Australia**
Origin	**Peak Peptides Australia**
Batch	**CP012606261810L**
Label claim	**10 mg**



VIAL AS RECEIVED — LD-ZACL

TESTS REQUESTED

Identity (LC-MS), purity (HPLC) and per-compound content (HPLC) of a peptide vial or vials.

02 / RESULTS

PURITY (HPLC)
99.79%
Whole vial

IDENTITY (LC-MS)
2 of 2
Compounds confirmed

CONTENT (HPLC)
2 compounds
Per compound below

DETAILED FINDINGS

COMPOUND	LABEL CLAIM	MEASURED	OF CLAIM	IDENTITY
BPC-157	5 mg	4.69 mg	93.8%	Confirmed
TB-500	5 mg	4.659 mg	93.18%	Confirmed

OVERALL ASSESSMENT — **Pass**

03 / ANALYSIS & VERIFICATION

Analysis by **Samir Dhakal, Apex Labs**
Analysis conducted: 20 OCTOBER 2026
Report Compiled by **Lab Doc Aus Pty Ltd**, 21 OCTOBER 2026

This report covers the tested sample only. LabDoc does not sell, supply or endorse any product or supplier, and this report is not a statement that any product is lawful, safe or suitable for use.